Tengion, Inc. announced unaudited earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations of $4,078,000, net loss of $11,935,000 or $3.59 per basic and diluted share, adjusted net loss of $5,815,000 or $1.75 per basic and diluted share compared to the loss from operations of $4,809,000, net loss of $17,855,000 or $0.82 per basic and diluted share, adjusted net loss of $6,534,000 or $0.3 per basic and diluted share for the same quarter a year ago.

For the six months period, the company reported loss from operations of $8,221,000, net loss of $17,709,000 or $5.84 per basic and diluted share, adjusted net loss of $11,350,000 or $3.74 per basic and diluted share compared to the loss from operations of $9,218,000, net loss of $53,113,000 or $2.96 per basic and diluted share, adjusted net loss of $12,745,000 or $0.72 per basic and diluted share for the same period a year ago.

The company announced six-month interim data for the first five patients with advanced CKD implanted in the Phase 1 clinical trial being conducted at the Karolinska Institute in Stockholm, Sweden. NKA cellular therapy was successfully implanted into one kidney of each patient. Four surgical procedure-related serious adverse events were recorded in this trial. None of these events were determined to be related to the NKA material and none caused the patients to discontinue the trial or the Data Safety Monitoring Board to stop the trial. None of the reported adverse events were kidney-related. The company has completed enrollment in its ongoing Phase 1 clinical trial for the Neo-Urinary Conduit. Bladder cancer patients were enrolled in the trial to assess the safety and preliminary efficacy of the Neo-Urinary Conduit, as well as to translate the surgical implantation procedure utilized in preclinical studies. The Company is working with key opinion leaders on future development plans for the Neo-Urinary Conduit, and will seek to execute a strategic or financial transaction to provide targeted funding for future development of the Neo-Urinary Conduit. In the absence of such funding, the Company does not plan to continue independent development of the Neo-Urinary Conduit program.